This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
by Zacks Equity Research
eFFECTOR Therapeutics (EFTR) plunges on disappointing top-line results from the primary analysis of its mid-stage NSCLC study of tomivosertib, following the abandonment of the developmental program.
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III
by Kinjel Shah
FDA approves AstraZeneca's (AZN) Voydeya (danicopan) in the United States as add on therapy to its other C5 inhibitors. Merck (MRK) begins a phase III study on its oral KRAS G12C inhibitor candidate.
Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate
by Zacks Equity Research
Merck's (MRK) phase III study will evaluate KRAS G12C inhibitor candidate MK-1084 for first-line treatment of certain patients with metastatic NSCLC.
Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA
by Zacks Equity Research
Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024. The stock surges 63.4%.
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
by Zacks Equity Research
Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug
by Zacks Equity Research
Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) reachead $129.90 at the closing of the latest trading day, reflecting a -0.35% change compared to its last close.
Why Merck (MRK) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merck (MRK) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Merck (MRK) reachead $131.95 at the closing of the latest trading day, reflecting a +0.15% change compared to its last close.
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
by Kinjel Shah
While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Company News for Mar 28, 2024
by Zacks Equity Research
Companies In The News Are: HOOD, COIN, MRK, NCNO.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Merck & Co. (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair
by Zacks Equity Research
Merck's (MRK) Winrevair becomes the first novel activin signaling inhibitor approved by the FDA to treat PAH.
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
by Zacks Equity Research
AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
by Zacks Equity Research
Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $123.85 in the latest trading session, marking a +0.19% move from the prior day.
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
by Kinjel Shah
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer Study
by Zacks Equity Research
Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure.
The Zacks Analyst Blog Highlights JPMorgan Chase, Merck, SAP, Lam Research and Brown-Forman
by Zacks Equity Research
JPMorgan Chase, Merck, SAP, Lam Research and Brown-Forman are included in this Analyst Blog.
Merck (MRK) Laps the Stock Market: Here's Why
by Zacks Equity Research
Merck (MRK) concluded the recent trading session at $123.85, signifying a +1.35% move from its prior day's close.
Top Research Reports for JPMorgan Chase, Merck & SAP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Merck & Co., Inc. (MRK) and SAP SE (SAP).
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
by Zacks Equity Research
AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.